

## Integrating large- to high- dimension markers in mecanistic models



Mélanie Prague, Auriane Gabaut, Lisa Crépin, Boris Hejblum, Rodolphe Thiébaut and Cécile proust-Lima

**Pharmacometrics in France – 19 Sept. 2025**



01

# INTRODUCTION AND MOTIVATION

# Motivations - Vaccinometrics

Starting point : Vaccine development for treatment and control of infectious diseases

- How it works ?
- How long ?
- How to predict the response in each individual ?
- What is the optimal vaccination strategy ?



# Mechanistic models – Population approach


## □ Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t = 0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$

# Mechanistic models – Population approach

## □ Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t = 0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$







# Mechanistic models – Population approach

## □ Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t = 0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$



$$\frac{dS}{dt} = -\delta_S S$$

$$\frac{dL}{dt} = -\delta_L L$$



$$S(t = 0) = S_0$$

$$L(t = 0) = L_0$$

# Mechanistic models – Population approach

## □ Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t = 0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$



$$\frac{dS}{dt} = -\delta_S S$$

$$S(t = 0) = S_0$$

$$\frac{dL}{dt} = -\delta_L L$$

$$L(t = 0) = L_0$$

$$\frac{dAb}{dt} = \theta_S S + \theta_L L - \delta_{Ab} Ab$$


$$Ab(t = 0) = 0$$

$$\theta = (\delta_S, \delta_L, \theta_S, \theta_L, \delta_{Ab})$$

# Mechanistic models – Population approach


## □ Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t = 0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$



## □ Statistical model (linear mixed effect model)

$$\begin{aligned} g(\theta_i(t)) &= g(\theta_0) + \phi Z_i(t) + u_i \\ u_i &\sim N(0, \Omega), \quad i \in \{1, \dots, N\} \end{aligned}$$





# Mechanistic models – Population approach




## Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t=0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$

## Statistical model (linear mixed effect model)

$$g(\theta_i(t)) = g(\theta_0) + \phi Z_i(t) + u_i$$

$$u_i \sim N(0, \Omega), \quad i \in \{1, \dots, N\}$$



Ensure positiveness of rates

$$\log(\theta_{Si}) = \log(\theta_{S0}) + \beta_{AGE} AGE_i + u_i$$

Population average value

Effect of covariates


$$u_i \sim N(0, \omega)$$

Residual heterogeneity  
Random effect

# Mechanistic models – Population approach


## □ Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t=0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$




## □ Statistical model (linear mixed effect model)

$$\begin{aligned} g(\theta_i(t)) &= g(\theta_0) + \phi Z_i(t) + u_i \\ u_i &\sim N(0, \Omega), \quad i \in \{1, \dots, N\} \end{aligned}$$



## □ Observation model (Error model)


$$\begin{aligned} Y_{ij} = Y(t_{ij}) &= h(X(t_{ij}, \theta)) + g(X(t_{ij}, \theta), \Sigma) \epsilon_{ij} \\ \epsilon_{ij} &\sim N(0, 1) \end{aligned}$$



# Mechanistic models – Population approach


## Structural model (ODE-based)

$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t=0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$





## Statistical model (linear mixed effect model)

$$\begin{aligned} g(\theta_i(t)) &= g(\theta_0) + \phi Z_i(t) + u_i \\ u_i &\sim N(0, \Omega), \quad i \in \{1, \dots, N\} \end{aligned}$$



## Observation model (Error model)

$$\begin{aligned} Y_{ij} = Y(t_{ij}) &= h(X(t_{ij}, \theta)) + g(X(t_{ij}, \theta), \Sigma) \epsilon_{ij} \\ \epsilon_{ij} &\sim N(0, 1) \end{aligned}$$



$$\begin{aligned} Y_{ij} &= \log_{10}(Ab(\theta_i, t)) + \epsilon_{ij} \\ \epsilon_{ij} &\sim N(0, \sigma) \end{aligned}$$



# Mechanistic models – Population approach

## Structural model (ODE-based)




$$\begin{cases} \frac{dX_k}{dt} = f_k(X_1, \dots, X_K, \theta, t), & X_k \in X \\ X_k(t=0) = X_{k,0}, & k \in \{1, \dots, K\} \end{cases}$$

## Statistical model (linear mixed effect model)


$$\begin{aligned} g(\theta_i(t)) &= g(\theta_0) + \phi Z_i(t) + u_i \\ u_i &\sim N(0, \Omega), \quad i \in \{1, \dots, N\} \end{aligned}$$

## Observation model (Error model)

$$\begin{aligned} Y_{ij} = Y(t_{ij}) &= h(X(t_{ij}, \theta)) + g(X(t_{ij}, \theta), \Sigma) \epsilon_{ij} \\ \epsilon_{ij} &\sim N(0, 1) \end{aligned}$$



Inverse





$$\begin{aligned} Y_{ij} &= \log_{10}(Ab(\theta_i, t)) + \epsilon_{ij} \\ \epsilon_{ij} &\sim N(0, \sigma) \end{aligned}$$


# Rationale & Objective



**High frequency transcriptomics (RNA-seq)** from self collected finger-prick blood  
Study: COVERAGE-Immuno



Good concordance between  
the **whole-blood** Tempus and  
Finger **prick-test**




Reasonable concordance  
between **cell abundance** by  
ICS and from transcriptomic  
data after deconvolution




# Rationale & Objective




**High frequency transcriptomics** (RNA-seq) from self collected finger-prick blood  
 Study: COVERAGE-Immuno



Good concordance between the **whole-blood** Tempus and Finger **prick-test**



Reasonable concordance between **cell abundance** by ICS and from transcriptomic data after deconvolution




Baseline transcriptomics data as covariates in the mechanistic model.

R package Lasso-SAMBA


# Rationale & Objective




**High frequency transcriptomics** (RNA-seq) from self collected finger-prick blood  
 Study: COVERAGE-Immuno



Good concordance between the **whole-blood** Tempus and Finger **prick-test**



Reasonable concordance between **cell abundance** by ICS and from transcriptomic data after deconvolution




# 02

Using transcriptomic data as  
explanatory covariates  
(lasso-SAMBA Package)



# Model Building strategy

Use baseline Gene expression as explanatory covariates




# Method

## Algorithms :

- SCM, *Stepwise Covariate Modeling* (Svensson and Jonsson, 2022) ;
- COSSAC, *COnditional Sampling use for Stepwise Approach based on Correlation tests* (Ayrat and al. 2021) ;
- **SAMBA (Prague and Lavielle, 2022).**

**SAMBA**, *Stochastic Approximation for Model Building Algorithm*, is an **iterative** algorithm, learning from a previous "worse" model in order to move towards a relevant model (Prague and Lavielle, 2022).





# Simulations

Covariates effects :



- $AGE \sim \mathcal{N}(35, 4^2)$  on  $\varphi_S$ ,
- $G_1 \sim \mathcal{N}(0, 1)$  on  $\varphi_L$
- $G_2 \sim \mathcal{N}(0, 1)$  on  $\delta_{Ab}$

P = 200 gaussian **correlated** covariates (P=1000 similar results)

R = 100 replicates,

N = 100 individuals (N=20 similar results).

Antibodies secreting cells (ASCs)



# Simulations

Parameter-Covariate link	Selected in the final model	NOT selected in the final model
In the generation model	True Positive (TP)	False Negative (FN)
NOT in the generation model	False Positive (FP)	True Negative (TN)

False Discovery Rate :  $FDR = \frac{FP}{TP + FP}$

False Negative Rate :  $FNR = \frac{FN}{TN + FN}$

F1-score :  $F1_{score} = \frac{2TP}{2TP + FN + FP}$



# Simulations

## Error Rate Comparison Table


Rate	Median	Confidence Interval (quantiles 95%)
False Discovery Rate : - stepAIC with stat. test - Lasso : $E[\text{FDR}] < 10\%$	72.7% 0.0%	[50.0%;83.8%] [0.0%;25.0%]
False Negative Rate : - stepAIC with stat. test - Lasso : $E[\text{FDR}] < 10\%$	0.0% 0.0%	[0.0%;0.0%] [0.0%;0.0%]
F1 score : - stepAIC with stat. test - Lasso : $E[\text{FDR}] < 10\%$	42.9% 100.0%	[27.9%;66.7%] [85.7%;100.0%]
<ul style="list-style-type: none"> <li>Final Final model without any False Negatives :               <ul style="list-style-type: none"> <li>- stepAIC with stat. test : 99%</li> <li>- Lasso : <math>E[\text{FDR}] &lt; 10\%</math> : 100%</li> </ul> </li> <li>Final model is the true one :               <ul style="list-style-type: none"> <li>- stepAIC with stat. test : 0%</li> <li>- Lasso : <math>E[\text{FDR}] &lt; 10\%</math> : 81%</li> </ul> </li> </ul>		

*Covariates presence in final model with parameters link*

Among 100 simulated datasets of humoral immune response to prime-boost of Ad26.ZEBOV/MVA-BN-FILO vaccine against Ebola for 100 individuals, with 200 gaussian correlated covariates.

## Computation Time Comparison



Among 100 simulated datasets of humoral immune response to prime-boost of Ad26.ZEBOV/MVA-BN-FILO vaccine against Ebola for 100 individuals, with 200 gaussian correlated covariates.





# Application to vaccine study : VZV

- Clinical study of immune response to vaccination against the **Varicella-Zoster Virus (VZV)**
- **Gene expression and antibody response data** following immunization with ZOSTAVAX, a live attenuated vaccine.
- **35 adult** volunteers, **6 datapoints** at day 0, 7, 14, 30, 90, and 180




# Application to vaccine study : VZV

10,086 profiled genes

a subset of **784 protein-coding genes** was selected based on functional annotation with roles in

- Interferon signaling,
- Type I Interferon response,
- Neutrophil activation,
- Inflammation,
- Cytokine/chemokine activity,
- and Cell cycle regulation



ASSOCIATED GENES : KIFC1 & LEP





# Interpretation

- The LEP gene is a player in several common biological pathways involved in the immune response such as JAK-STAT or NFkB.
- KIFC1 is involved in cell proliferation and therefore is not specific of immune response. KIFC1 also has the ability to promote stable mitotic spindle formation during early B cell development where centriole duplication is frequent but must be tightly regulated



Francisco et al. Obesity, Fat Mass and Immune System: Role for Leptin. *Frontiers in Physiology*. 2018

Lam et al. Role of leptin in immunity. *Cell Mol Immunol*. 2007

Lucanus et al. Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics. *Oncogene*. 2018

Wu et al. An integrative pan-cancer analysis of kinesin family member C1 (KIFC1) in human tumors. *Biomedicines*. 2022

Hagan et al. Transcriptional atlas of the human immune response to 13 vaccines reveals predictor of vaccine-induced Ab responses. *Nature Immunology*. 2022

03




Toward high dimension  
mechanistic models using latent  
class models  
(REmixed Package)



# Motivating study

Evaluation of COVID-19 vaccine




15 adults receiving COVID-19 Pfizer vaccine






# Motivating study

Evaluation of COVID-19 vaccine

15 adults receiving COVID-19 Pfizer vaccine




6000+ genes; 34 gene sets





# Method Idea

Use longitudinal Gene expression as observation of latent compartments



## Observation Model

For each individual  $i \leq N$ ,  $k \leq K$  times  $(t_{ij})_{j \leq n_i}, (t_{ijk})_{j \leq n_{ki}}$ :

$$Y_{ij} = h\left(Ab_i(t_{ij})\right) + \epsilon_{ij}$$

$$G_{kij} = \alpha_{0k} + \alpha_{1k} S_i(t_{ijk}) + \epsilon_{ijk}$$

where  $\epsilon = (\epsilon_{ij})_{i \leq N, j \leq n_i} \sim \mathcal{N}(0, \Sigma^2)$

$$\epsilon_k = (\epsilon_{ijk})_{i \leq N, j \leq n_{ik}} \sim \mathcal{N}(0, \sigma_k^2).$$

Simultaneous estimation of model parameters are  $\theta = (\psi_{pop}, \beta, \Omega, (\sigma_k^2)_{k \leq K}, (\Sigma_p^2)_{p \leq P}, (\alpha_{0k})_{k \leq K})$   
 and the regularized parameters  $\alpha = (\alpha_{1k})_{k \leq K}$  by maximizing log-likelihood under lasso penalization :

$$LL_{pen}(\theta, \alpha) = LL(\theta, \alpha) - \lambda |\alpha|$$



# REMixed Algorithm – cyclic descent algorithm

$$LL_{pen}(\theta, \alpha) = LL(\theta, \alpha) - \lambda|\alpha|$$

For a given **penalty parameters**  $\lambda$ , the iteration  $l$  in the estimation procedure correspond to :

At iteration  $l$  :

Current parameters are  $\theta^{(l)}, \alpha_1^{(l)}$ .

1. Update  $\alpha_1^{(l+1)}$  for fixed  $\theta = \theta^{(l)}$  using **update formula derived from penalized log-likelihood maximization**.
2. Update  $\theta^{(l+1)}$  for fixed  $\alpha_1 = \alpha_1^{(l+1)}$  using **SAEM algorithm through Monolix software**.

We continue itérations until :



- $\left\| \left( \theta^{(l+1)}, \alpha_1^{(l+1)} \right) - \left( \theta^{(l)}, \alpha_1^{(l)} \right) \right\|_2 \leq \varepsilon_1$  (parameters stability)
- $\left| LL_{pen} \left( \theta^{(l+1)}, \alpha_1^{(l+1)} \right) - LL_{pen} \left( \theta^{(l)}, \alpha_1^{(l)} \right) \right| \leq \varepsilon_2$  (penalised log-likelihood stability)

# REMixed Algorithm – Choice of lambda

Presented procedure was given a penalty parameter  $\lambda$ .

For  $\Lambda = \left\{ \lambda_l = \lambda_{max} \times \alpha_{\lambda}^{\frac{l}{N\lambda}}; 1 \leq l \leq N \right\}$ , with  $\lambda_{max} = \max(\partial_{\alpha} LL(\theta^{(0)}, \alpha) |_{\alpha=0_K})$ ,

$$BICc(\lambda) = -2LL(\theta^*, \alpha^*) + \log(N) \dim(\theta_R) + \log(n_{tot}) \dim(\theta_F)$$



A final SAEM is then computed followed by statistical test to remove non-significant biomarkers.



# Simulations setting

**Structural Model** 25 individuals, 50 biomarkers – 10 informative biomarkers , 200 replicates





$$\begin{aligned}
 \dot{S}_i(t) &= -\delta_{S_i} S_i(t) & \log(\delta_{S_i}) &= \log(\delta_{S_{pop}}) + \eta_i^S \\
 \dot{Ab}_i(t) &= \varphi_{S_i} S_i(t) - \delta_{Ab_i} Ab_i(t) & \log(\delta_{Ab_i}) &= \log(\delta_{Ab_{pop}}) + \eta_i^{Ab} \\
 S(t=0) &= 5 & \log(\varphi_{S_i}) &= \log(\varphi_{S_{pop}}) + \eta_i^\varphi \\
 Ab(t=0) &= 1000
 \end{aligned}$$

## Statistical Model


$$\eta_i^\chi \sim \mathcal{N}(0, \omega_\chi^2), \quad \chi \in \{S, Ab, \varphi\}$$

**Observation Model**  $t_j \in \{0, 7, 21, 123, 180, 300\}$  ;  $t'_j \in \{0, \dots, 21\}$

$$\begin{aligned}
 Y_{ij} &= \log_{10}(Ab_i(t_j)) + \varepsilon_{ij} & (\varepsilon_{ij}) &\sim \mathcal{N}(0, \sigma_{Ab}^2) \text{ iid} \\
 G_{kij} &= \alpha_{0k} + \alpha_{1k} S_i(t'_j) + \varepsilon_{kij} & (\varepsilon_{kij}) &\sim \mathcal{N}(0, \sigma_{G_k}^2) \text{ iid}
 \end{aligned}$$



# Simulations results





04

## Conclusions and perspectives

## Perspectives

- Packages lasso-SAMBA and Remixed have been released on CRAN



CRAN lasso-SAMBA



CRAN REMixed

- Find relevant application of these methods (including in pharmacogenomics) and evaluate if assumptions can/have to be relaxed (ie. Linear relationship).

$$\text{Lasso-SAMBA } g(\theta_i(t)) = g(\theta_0) + \textcolor{red}{h}(X_i(t)) + u_i$$

$$\text{REMixed } G_{kij} = \textcolor{red}{h}(S_i(t'_j), \varepsilon_{kij})$$

# Acknowledgment

This project was funded by RRI impulsion and EDCTP PREVAC

## Inria/Inserm

Cécile Proust-Lima

Lisa Crépin

Boris Hejblum

Rodolphe Thiébaut

Auriane Gabaut



Digital Public  
Health  
Graduate Program



## Vaccine Research Institute

Yves Levy

Christine Lacabartz

Sylvain Cardinaud

Mathieu Surenaud

Séverin Coleon

Véronique Godot

Mireille Centlivre

Olivier Schwartz



Simulation+ / Lixoft Monolix Suite





# Acknowledgements


# Thank you !

**WE ARE HIRING POSTDOCS IN BIOSTATISTICS  
/ MODELING / PHARMACOMETRICS  
([MELANIE.PRAGUE@INRIA.FR](mailto:MELANIE.PRAGUE@INRIA.FR))**







# 2 Method : Lasso Selection




Individual Parameter regression :

We have a previously build model  $\mathcal{M}_k$  at iteration  $k$ , with parameters  $\theta^{(k)}$ ,  $(\psi_i^{(k)})_{i \leq N}$ ; we write the regression model **for each parameter** :

$$g(\psi_i^{(k)}) = g_l(\psi_{pop}^{(k)}) + \beta X_i$$



# 2 Method : Lasso Selection



Individual Parameter regression :

We have a previously build model  $\mathcal{M}_k$  at iteration  $k$ , with parameters  $\theta^{(k)}$ ,  $(\psi_i^{(k)})_{i \leq N}$ ; we write the regression model **for each parameter** :


$$g(\psi_i^{(k)}) = g_l(\psi_{pop}^{(k)}) + \beta X_i$$

Lasso Regression :

We then compute the lasso estimator

$$\hat{\beta} = \arg \min_{\beta \in \mathbb{R}^n} \left\{ \sum_{i \leq N} \left( g(\psi_i^{(k)}) - g(\psi_{pop}^{(k)}) - \beta X_i \right)^2 + \lambda |\beta|_1 \right\}$$


Where  $\lambda > 0$  is a data-driven penalization parameter.






## 2 Method : Stability Selection

For a given  $\lambda$




## 2 Method : Stability Selection

For a given  $\lambda$



# 2 Method : Stability Selection


For a given  $\lambda$





## 2 Method : Stability Selection

For a given  $\lambda$



## 2 Method : Parameters calibration and IC

Lasso selection enhanced by stability selection depends on two parameters

$\lambda$  the penalization parameter  
 $t_{ss}$  the selection thresholds

## 2 Method : Parameters calibration and IC

Lasso selection enhanced by stability selection depends on two parameters

$\lambda$  the penalization parameter  
 $t_{ss}$  the selection thresholds

! Decreasing IC in covariate selection step by step AIC in SAMBA seems to allow algorithm to stop.

> Rather than one single model, we construct a set of relevant models to explore, searching for one decreasing the IC.



## 2 Method : Parameters calibration and IC

Lasso selection enhanced by stability selection depends on two parameters

$\lambda$  the penalization parameter  
 $t_{ss}$  the selection thresholds

! Decreasing IC in covariate selection step by step AIC in SAMBA seems to allow algorithm to stop.

> Rather than one single model, we construct a set of relevant models to explore, searching for one decreasing the IC.


**Meinshausen and Bühlmann, 2010 :**

$$\mathbb{E}[\#FP(\mathcal{S}^{\lambda, t_{ss}})] \leq U_{\lambda, t_{ss}} = \frac{1}{2t_{ss} - 2} \times \frac{q_{\lambda}^2}{n}$$


Where  $q_{\lambda}$  is the average number of features that are selected at least once by the Lasso algorithm, and  $n$  the number of covariates.

## 2 Method : Parameters calibration and IC

Selected set  $\mathcal{S}_{\lambda, t_{SS}}$  of  
covariates by Lasso




## 2 Method : Parameters calibration and IC






## 2 Method : Parameters calibration and IC



# 2 Method : Parameters calibration and IC



## 2 Method : REMix algorithm

Update formula of regularized parameters.

At this step, we suppose fixed  $\theta^{(l)}$ , and current estimate  $\alpha^{(l)}$

We want to solve

$$\partial_{\alpha_1}(LL(\theta^{(l)}, \alpha) - \lambda|\alpha|) = 0$$

We use a second order Taylor development

$$LL(\theta^{(l)}, \alpha) = LL(\theta^{(l)}, \alpha^{(l)}) + (\alpha - \alpha^{(l)})^T \partial_{\alpha} LL(\theta^{(l)}, \alpha) \Big|_{\alpha=\alpha^{(l)}} - \frac{1}{2} (\alpha - \alpha^{(l)})^T \partial_{\alpha}^2 LL(\theta^{(l)}, \alpha) \Big|_{\alpha=\alpha^{(l)}} (\alpha - \alpha^{(l)})$$

The update formula for regularized parameters  $\alpha_{1k}$  :

$$\alpha_{1k}^{(l+1)} = \begin{cases} \frac{A + \lambda}{\partial_{\alpha_{1k}}^2 LL(\theta^{(l)}, \alpha) \Big|_{\alpha=\alpha^{(l)}}}, & \text{if } A < -\lambda \\ \frac{A - \lambda}{\partial_{\alpha_{1k}}^2 LL(\theta^{(l)}, \alpha) \Big|_{\alpha=\alpha^{(l)}}}, & \text{if } A < +\lambda \\ 0, & \text{otherwise.} \end{cases}$$

With  $A$  a function of gradient, hessian and current estimates.



# 3 Simulation Studies

## Initialization Strategy

- We randomly group genes by pairs and run a SAEM algorithm for each pair.
- The initialization yielding the best log-likelihood is selected to launch the final algorithm.

